drugset / Trial / NCT07473973
ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Timeline
- Start
- 2025-03-26
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
Outcome
Outcome not reported
Stopped: “Following review of the totality of program data, the sponsor decided to discontinue development of INZ701. The decision was not related to safety.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INZ-701 | Protein / enzyme biologic | — | Subcutaneous |